Korbet S M, Schwartz M M, Lewis E J
Department of Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612.
Am J Kidney Dis. 1994 Jun;23(6):773-83. doi: 10.1016/s0272-6386(12)80128-4.
Primary focal segmental glomerulosclerosis (FSGS) is a lesion associated with a poor prognosis and results in end-stage renal disease after 5 to 10 years. Based on past experience, many nephrologists have considered primary FSGS a lesion that is steroid resistant and therefore are reluctant to offer steroids as treatment. Recent data, however, have demonstrated that patients with primary FSGS have a response to steroid therapy that is considerably better than had been described. Thus, it may be that nephrologists have been more "steroid reluctant" than the lesion is steroid resistant. To better understand this issue we review the clinical course and response to therapy in patients with primary FSGS.
原发性局灶节段性肾小球硬化(FSGS)是一种预后较差的病变,5至10年后会导致终末期肾病。根据以往经验,许多肾脏病学家认为原发性FSGS是一种对类固醇耐药的病变,因此不愿使用类固醇进行治疗。然而,最近的数据表明,原发性FSGS患者对类固醇治疗的反应比之前描述的要好得多。因此,可能是肾脏病学家比该病变对类固醇的耐药性更“抗拒使用类固醇”。为了更好地理解这个问题,我们回顾了原发性FSGS患者的临床病程及治疗反应。